Merck & Company (MRK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Merck & Company (MRK)

119.60

+0.08 (0.07%)

as of Jun 9, 2026, 8:00:00 pm Market Open.

310 watching

Investor Insights

Jun 9, 2026, 12:00 am

This summary was created by AI, based on 21 opinions in the last 12 months.

Merck & Company (MRK) is widely recognized for its robust drug pipeline, particularly in the oncology space, despite concerns surrounding the impending patent expiration of its blockbuster drug Keytruda in 2028, which currently accounts for a significant portion of its revenue. Experts express mixed sentiments on its future performance; while some highlight the strong growth prospects from various drugs in the pipeline and strategic acquisitions, others point to risks and valuation concerns in light of the upcoming patent cliff. Analysts have shown optimism regarding MRK's capacity to sustain revenue growth post-Keytruda, often citing its decent dividend yield and potential for substantial upside. Overall, the company has been recommended as a solid investment, with a call for cautious management of positions amid broader market uncertainty and clarity on US drug pricing affecting the pharmaceutical sector.

Consensus

Bullish

Valuation

Undervalued

Similar

Pfizer, PFE

PAST TOP PICK

(Was a top pick on May 21/03. Up 4.4%.) Still likes. Offers good value.

TOP PICK

2.5% dividend. Big name products. Only 14/15 X next years earnings. Recent studies suggest that some of their drugs may also be useful in preventing cancer.

TOP PICK

Trading at 16 X earnings, yielding 2.6%. Great pipeline of new drugs. Great balance sheet.

BUY

Good price. Good earnings price momentum.

TOP PICK

Health care sector is a good sector. 15/16 PE. Good price.

WEAK BUY

Some of their drugs have come off patent and they are having difficulty with Research /Development productivity. Prefers Pfizer.

TOP PICK

Pharmaceuticals look good in any upturn. 3% dividend. Trading at 15 X earnings. Had no earnings growth this year.

BUY

Demographics for pharmaceuticals is good. Could be volatile during their election period. Good long term.

BUY

Likes the valuations. Good balance sheet and good earnings.

BUY

Outlook for drug companies is good. A bit expensve, but long term is good.

BUY

Sector has been hit hard. At a good level. Prefers Pfizer.

PAST TOP PICK

(Was a top pick on Apr 4 up 1.5%) Still likes.

DON'T BUY

Very reasonable valuation. Patents are coming off. Prefers Pfizer.

DON'T BUY

Fairly cheap. Dividend. Several drugs coming off patent.

BUY

At a 5 year low. Have some good products. At a good price.

Showing 271 to 285 of 304 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Barry Schwartz

Baskin Wealth Management

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Merck & Company (MRK)